Invivyd (IVVD) Other Gross PP&E Adjustments (2020 - 2025)
Invivyd posted quarterly Other Gross PP&E Adjustments of -$21.3 million for Q4 2025, down 12.39% year-on-year from -$24.3 million in Q4 2024, and down 681.16% on a QoQ basis from -$2.7 million in Q3 2025.
Invivyd (IVVD) has 6 years of Other Gross PP&E Adjustments data on file, last reported at -$21.3 million in Q4 2025.
- For the quarter ending Q4 2025, Other Gross PP&E Adjustments fell 12.39% year-over-year to -$21.3 million; the trailing twelve-month figure through Dec 2025 stood at -$21.3 million (down 12.39% YoY), and the FY2025 full-year result was -$21.3 million, down 12.39% from the prior year.
- Other Gross PP&E Adjustments for Q4 2025 stood at -$21.3 million, down from -$2.7 million in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at -$782000.0 in Q2 2024 and bottomed at -$21.3 million in Q4 2025.
- The 5-year median for Other Gross PP&E Adjustments is -$2.9 million (2022), against an average of -$5.8 million.
- The widest annual swing landed in 2021, when Other Gross PP&E Adjustments slumped 13177.42%; it then soared 74.05% in 2024.
- A 5-year view of Other Gross PP&E Adjustments shows it stood at -$4.1 million in 2021, then tumbled by 193.61% to -$12.1 million in 2022, then sank by 33.64% to -$16.2 million in 2023, then decreased by 17.41% to -$19.0 million in 2024, then dropped by 12.39% to -$21.3 million in 2025.
- The last three Other Gross PP&E Adjustments figures came in at -$21.3 million (Q4 2025), -$2.7 million (Q3 2025), and -$3.0 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -189.30 Mn |
| 10 | Invivyd | 208.38 Mn | -18.31 Mn | - | -21.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -21.31 Mn |
| Dec 31, 2025 | -21.31 Mn |
| Sep 30, 2025 | -2.73 Mn |
| Sep 30, 2025 | -2.73 Mn |
| Jun 30, 2025 | -3.01 Mn |
| Jun 30, 2025 | -3.01 Mn |
| Mar 31, 2025 | -953,000.00 |
| Mar 31, 2025 | -953,000.00 |
| Dec 31, 2024 | -18.96 Mn |
| Dec 31, 2024 | -18.96 Mn |
| Sep 30, 2024 | -1.73 Mn |
| Sep 30, 2024 | -1.73 Mn |
| Jun 30, 2024 | -782,000.00 |
| Jun 30, 2024 | -782,000.00 |
| Mar 31, 2024 | -1.83 Mn |
| Mar 31, 2024 | -1.83 Mn |
| Dec 31, 2023 | -16.15 Mn |
| Dec 31, 2023 | -16.15 Mn |
| Sep 30, 2023 | -2.63 Mn |
| Sep 30, 2023 | -2.63 Mn |
| Jun 30, 2023 | -3.01 Mn |
| Jun 30, 2023 | -3.01 Mn |
| Mar 31, 2023 | -3.40 Mn |
| Mar 31, 2023 | -3.40 Mn |
| Dec 31, 2022 | -12.09 Mn |
| Dec 31, 2022 | -12.09 Mn |
| Sep 30, 2022 | -1.49 Mn |
| Sep 30, 2022 | -1.49 Mn |
| Jun 30, 2022 | -2.86 Mn |
| Jun 30, 2022 | -2.86 Mn |
| Mar 31, 2022 | -1.65 Mn |
| Mar 31, 2022 | -1.65 Mn |
| Dec 31, 2021 | -4.12 Mn |
| Dec 31, 2021 | -4.12 Mn |
| Dec 31, 2020 | -31,000.00 |
| Dec 31, 2020 | -31,000.00 |